Results 171 to 180 of about 72,467 (253)

Addressing the Challenges of Translating LRRK2 Biology into Disease‐Modifying Therapies: The LRRK2 Investigative Therapeutics Exchange Initiative

Movement Disorders, EarlyView.
Esther Sammler, Francesca Tonelli, Michelle Durborow, Jim McNasby, Todd Sherer, Mahmood Ahmed, Stevan W. Djuric, Kalpana Merchant, Alastair Reith, Darryle Schoepp, Christine Klein, Shalini Padmanabhan, Dario R. Alessi   +12 more
wiley   +1 more source

Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease‐directed progress

British Journal of Haematology, EarlyView.
Summary Over the past decade, there has been a substantial increase in the diversity and number of therapeutic options for myeloproliferative neoplasms (MPNs). While many remain within the clinical trial arena, the clinician and patient community have seen more approvals reaching the clinic and a rethink on how best we should be approaching these ...
Trung Q. Ngo, Maria Georgiou, Donal P. McLornan, Claire N. Harrison   +3 more
wiley   +1 more source

Red lines and green lights: Gene therapy for inherited erythroid disorders beyond the haemoglobinopathies

British Journal of Haematology, EarlyView.
Gene therapy is revolutionizing treatment paradigms for haemoglobinopathies, establishing a translational framework for disorders that impact red blood cell development. In their paper, Joshi et al. describe the preclinical and early clinical landscape of gene therapies for non‐haemoglobinopathy erythroid disorders and highlight common thematic ...
Gaurav Joshi, Nandakumar Natarajan, Kathryn E. Dickerson, Richard A. Voit   +3 more
wiley   +1 more source

Peripheral targets for neuropathic pain

British Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour, Cosmin I. Ciotu, Felix J. Resch, Michael J. M. Fischer   +3 more
wiley   +1 more source

Building a precision therapeutics program at a tertiary care children's hospital

Pediatric Investigation, EarlyView.
Luke Hamilton, Heidi Trinkman, Diana Carrasco, Kaitlin Smith, Kelly Vallance, Alejandra Dominguez, Danielle Miller, Megan Gibbs, Anish Ray   +8 more
wiley   +1 more source

Long non‐coding RNAs at the crossroads of inflammation, cancer and angiogenesis: Molecular mechanisms and their potential as therapeutic targets

British Journal of Pharmacology, EarlyView.
Long non‐coding RNAs (lncRNAs), a broad class of non‐protein‐coding RNAs, are characterized as new regulators of gene expression at the epigenetic, transcriptional, and post‐transcriptional level. Thus, lncRNAs are involved in the regulation of physiological processes and the development of human diseases and cancer by modulating proinflammatory ...
Charlie Leboff, Pamela Calle‐Mendoza, Maria Hatziapostolou, Christos Polytarchou   +3 more
wiley   +1 more source

circMAN1A2 as an Isoform‐Resolved Circular RNA Hub in Cancer

Cancer Science, EarlyView.
circMAN1A2 as an isoform‐resolved circular RNA hub in cancer. circMAN1A2 is generated by back‐splicing of MAN1A2 pre‐mRNA, with alternative circularization producing multiple isoforms, including the predominant circMAN1A2(2–5). Its mechanistic interfaces include miRNA‐associated regulation, RBP binding/proteostasis control, BSJ‐mediated RNA–RNA pairing,
Hanyu Shang, Hui Wang, Yonghang Xu, Lingyun Geng, Yanqing Wang   +4 more
wiley   +1 more source

Tumor‐Derived Exosomal piR‐hsa‐28212 Promotes Lymphatic Metastasis in Breast Cancer

Cancer Science, EarlyView.
Breast cancer–derived exosomal piR‐hsa‐28212 promotes lymphangiogenesis and lymph node metastasis by activating VEGFC/VEGFR3 signaling. It stabilizes TBX1 mRNA in lymphatic endothelial cells and METTL3 protein in tumor cells, enhancing VEGFR3 expression and VEGFC secretion.
Yafen Wang, Tianli Zhang, Xue Kong, Yao Tong, Yanru Li, Xiangjun Dong, Chuanxin Wang, Juan Li   +7 more
wiley   +1 more source

FDX1 Depletion Activates CD8+ T Cell Antitumor Immunity by Promoting DMBT1 Secretion in Cuproptosis of Colorectal Cancer

Cancer Science, EarlyView.
Elesclomol‐induced cuproptosis potently activates both innate and adaptive antitumor immunity, especially CD8+ T cell immunity. FDX1 serves as a central regulator of CD8+ T cell functionality through DMBT1 downregulation during cuproptosis in colorectal cancer.
Jieqiong Wu, Zaixi Lian, Mingzhou Li, Xingtu Qin, Xiaoyu Lei, Lihua Yang, Lin Bing, Qiuyue Li, Lingyan Zhou, Zhiyang Ma, Xuemei Xu, Jinghao Huang, Zilong Chen, Lijie Chen, Lingjie Zhang, Zhiyuan Xiao, Xiangyu Jian, Xiaoqin Zhang, Yanqing Ding, Yaping Ye, Li Liang, Hongli Jiao, Shuyang Wang   +22 more
wiley   +1 more source

LMTK2 Inhibits Metastasis of Colon Cancer Cells Through p38 MAPK

Cancer Science, EarlyView.
LMTK2 suppresses colon cancer metastasis by acting as a kinase‐independent scaffold that directly binds p38, blocking its interaction with MKK3/6 and subsequent phosphorylation, thereby inhibiting the downstream pro‐metastatic gene program. ABSTRACT Metastasis is the leading cause of death in patients with colon cancer. Although Lemur tyrosine kinase 2
Jie Lun, Jinzhao Zhang, Jianxin Xu, Liyuan Jing, Yanqing Qin, Jing Fang, Mengchao Yu   +6 more
wiley   +1 more source